Trial Profile
A Randomized, Double-Blind, Placebo-controlled, Parallel, Exploratory Phase 2a Study to Evaluate Safety and Biological Effect on Wound Healing of ILP100 in Subjects with Diabetic Foot Ulcers
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Jan 2024
Price :
$35
*
At a glance
- Drugs Emilimogene sigulactibac (Primary)
- Indications Diabetic foot ulcer; Wounds
- Focus Adverse reactions
- Sponsors Ilya Pharma
- 20 Oct 2022 Status changed from planning to recruiting.
- 07 Jan 2021 According to an Ilya Pharma media release, this study is expected to begin in Q2 2021.
- 08 Jun 2020 According to an Ilya Pharma media release, the company aims to open recruitment for Phase II in 2021 and is also currently closing an additional related Euros 5 million share issue in the near future.